Vol 26, No 1 (2019)
Published online: 2019-03-14

open access

Page views 3094
Article views/downloads 1721
Get Citation

Connect on Social Media

Connect on Social Media

Bivalirudin use in acute coronary syndrome patients undergoing percutaneous coronary interventions in Poland: Clinical update from expert group of the Association on Cardiovascular Interventions of the Polish Cardiac Society

Łukasz Kołtowski1, Jacek Legutko2, Krzysztof J. Filipiak1, Artur Dziewierz3, Stanisław Bartuś4, Paweł Buszman45, Piotr Buszman67, Dariusz Ciećwierz8, Maciej Dąbrowski9, Sławomir Dobrzycki10, Robert Gil11, Jarosław Gorący12, Marek Grygier13, Miłosz Jaguszewski8, Janusz Kochman1, Jacek Kubica14, Wiktor Kuliczkowki15, Piotr Lodziński1, Andrzej Ochała16, Krzysztof Reczuch17, Adam Witkowski9, Wojciech Wojakowski18, Jarosław Wójcik19, Dariusz Dudek2021
Pubmed: 30882184
Cardiol J 2019;26(1):1-7.


Not available

Article available in PDF format

View PDF Download PDF file


  1. Sanchis-Gomar F, Perez-Quilis C, Leischik R, et al. Epidemiology of coronary heart disease and acute coronary syndrome. Ann Transl Med. 2016; 4(13): 256.
  2. Wożakowska-Kapłon B, Lesiak M, Ochała A, et al. [Bivalirudine use in the acute myocardial infarction in patients undergoing percutaneous coronary interventions: consensus statement of experts from the Cardiovascular Pharmacotherapy Working Group and the Association on Cardiovascular Interventions of the Polish Cardiac Society]. Kardiol Pol. 2014; 72(8): 761–765.
  3. Valgimigli M, Frigoli E, Leonardi S, et al. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Lancet. 2018; 392(10150): 835–848.
  4. Shah R, Jovin IS, Chaudhry A, et al. Safety and efficacy of switching from unfractionated heparin to bivalirudin during primary percutaneous coronary intervention. Catheter Cardiovasc Interv. 2019; 93(2): 241–247.
  5. Anantha-Narayanan M, Anugula D, Gujjula NR, et al. Bivalirudin versus heparin in percutaneous coronary intervention-a systematic review and meta-analysis of randomized trials stratified by adjunctive glycoprotein IIb/IIIa strategy. J Thorac Dis. 2018; 10(6): 3341–3360.
  6. Grajek S, Michalak M, Gwizdała A, et al. Patients treated with bivalirudin are still at higher risk of stent thrombosis: a comprehensive meta-analysis of randomised clinical trials of bivalirudin and heparin for percutaneous coronary interventions. Kardiol Pol. 2018; 76(4): 740–749.
  7. Neumann F-J, Ahlsson A, Alfonso F, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2018; 34(10): 2949.
  8. Kereiakes D, Yeh R, Massaro J, et al. Stent thrombosis in drug-eluting or bare-metal stents in patients receiving dual antiplatelet therapy. JACC: Cardiovasc Interv. 2015; 8(12): 1552–1562.
  9. Kam PCA, Kaur N, Thong CL. Direct thrombin inhibitors: pharmacology and clinical relevance. Anaesthesia. 2005; 60(6): 565–574.
  10. Alquwaizani M, Buckley L, Adams C, et al. Anticoagulants: A Review of the Pharmacology, Dosing, and Complications. Curr Emerg Hosp Med Rep. 2013; 1(2): 83–97.
  11. Cannon CP, Maraganore JM, Loscalzo J, et al. Anticoagulant effects of hirulog, a novel thrombin inhibitor, in patients with coronary artery disease. Am J Cardiol. 1993; 71(10): 778–782.
  12. Stratmann G, deSilva A, Tseng E, et al. Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia. Anesth Analg. 2004: 1635–1639.
  13. Valgimigli M, Frigoli E, Leonardi S, et al. Bivalirudin or Unfractionated Heparin in Acute Coronary Syndromes. N Engl J Med. 2015; 373(11): 997–1009.
  14. Erlinge D, Omerovic E, Fröbert O, et al. Bivalirudin versus Heparin Monotherapy in Myocardial Infarction. N Engl J Med. 2017; 377(12): 1132–1142.
  15. Witkowski A, Barylski M, Filipiak KJ, et al. Non-vitamin K antagonist oral anticoagulants (NOACs) in the treatment of coronary and peripheral atherosclerosis. Expert Consensus. Kardiol Pol. 2019 [Epub ahead of print].
  16. Mallifi JR, Lotfi AS. Management of STEMI in Patients on NOACs and Undergoing Primary PCI. Expert Analysis ACC website 2015. https://www.acc.org/latest-in-cardiology/articles/2015/10/22/10/43/management-of-stemi-in-patients-on-noacs-and-undergoing-primary-pci.
  17. Wojtasik-Bakalarz J, Kleczyński P, Zasada W, et al. Safety of bivalirudin versus unfractionated heparin in endovascular revascularization of peripheral arteries in short- and long-term follow-up. Advances in Inverventional Cardiology. .
  18. Stone GW, Maehara A, Witzenbichler B, et al. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA. 2012; 307(17): 1817–1826.
  19. Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med. 2008; 358(21): 2218–2230.
  20. Stone G, McLaurin B, Cox D, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med. 2006; 355(21): 2203–2216.
  21. Steg PG, van 't Hof A, Hamm CW, et al. Bivalirudin started during emergency transport for primary PCI. N Engl J Med. 2013; 369(23): 2207–2217.
  22. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361(11): 1045–1057.
  23. Wiviott S, Braunwald E, McCabe C, et al. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2007; 357(20): 2001–2015.
  24. Koster A, Faraoni D, Levy JH. Argatroban and bivalirudin for perioperative anticoagulation in cardiac surgery. Anesthesiology. 2018; 128(2): 390–400.
  25. Schwenkglenks M, Brazier JE, Szucs TD, et al. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes. Value Health. 2011; 14(1): 24–33.
  26. Borg S, Persson U, Allikmets K, et al. Comparative cost-effectiveness of anticoagulation with bivalirudin or heparin with and without a glycoprotein IIb/IIIa-receptor inhibitor in patients undergoing percutaneous coronary intervention in Sweden: a decision-analytic model. Clin Ther. 2006; 28(11): 1947–1959.